Eosinophilic Granulomatosis with Polyangiitis

This presentation offers a comprehensive overview of Eosinophilic Granulomatosis with Polyangiitis (EGPA)—a rare, systemic necrotizing vasculitis characterized by asthma, chronic rhinosinusitis, peripheral eosinophilia, and granulomatous inflammation affecting small- to medium-sized vessels. It explores the epidemiology, genetic predispositions, and environmental triggers, alongside the immunopathogenic mechanisms driving eosinophilic infiltration, Th2-mediated immune activation, and ANCA-associated vascular injury. Multi-organ involvement, including the lungs, skin, peripheral nerves, heart, and kidneys, is examined in detail.

Diagnostic strategies encompass clinical criteria, eosinophil counts, ANCA testing, imaging modalities, and tissue biopsy. Conventional management includes corticosteroids and immunosuppressants, with biologics targeting IL-5, IL-4/IL-13, and B-cell pathways representing significant advances. Beyond these established therapies, the presentation introduces novel regenerative and integrative strategies, including Precursor Stem Cell Therapy (PSCT), Autologous Active Specific Immunotherapy (AASI®), Nano Organo Peptides (NOP) Thymus and Mito Organelle (MO) Thymus for Thymus Therapy, Nano Organo Peptides (NOP) Super Transfer Factor (STF), Mito Organelles (MO) Super Transfer Factor (STF), and GcMAF Forte. Supported by scientific references and case-based insights, this program is designed for rheumatologists, pulmonologists, immunologists, and healthcare professionals seeking deeper expertise in EGPA pathogenesis and cutting-edge therapeutic frontiers.